New Medicine for AIDS Is One Pill, Once a Day
Date: 11.7.2006
The pill, which combines three drugs made by two companies, would be a milestone in improving the simplicity of treatment for the disease, experts say. It should make it easier for people to take their medicine regularly, which is important for keeping the virus that causes the disease in check.
Only a decade ago, when cocktails of AIDS drugs were first used, patients often had to take two or three dozen pills a day, some with food, some without, some so frequently patients had to get up in the middle of the night. Since then, the regimens have been whittled down to as few as two pills a day, and now, one.
"Going down to one pill a day is amazing," said Keith Folger of Washington, who started on 36 pills a day about 11 years ago and expects to switch to the new pill when it becomes available.
Mr. Folger, who is just leaving a job as director of community mobilization for the National Association of People With AIDS, said the pill would be "remarkable, especially for people who are starting on medication for the first time and are sort of freaked out that they will have to take pills for the rest of their lives."
The new drug is a combination of drugs already on the market — Sustiva, sold by Bristol-Myers Squibb, and Truvada, sold by Gilead Sciences. Truvada is a combination of two Gilead drugs, Viread and Emtriva.
The Food and Drug Administration is expected to approve the new drug as soon as this week. The agency has until October to act but is expected to do so much sooner, partly because the government has been encouraging companies to do just this sort of collaboration to come up with simpler AIDS drugs.
The companies have not revealed the new drug's name or its price, though they have suggested it will cost roughly the same as Sustiva and Truvada bought separately, which is about $1,200 a month.
There are already other AIDS pills that combine three drugs. One, made by a company in India, was recently approved by the F.D.A. for use in developing countries. But those other three-in-one pills generally contain older drugs and are taken twice a day.
The drugs in the new pill already constitute the most widely prescribed regimen in the United States and one of the most effective.
Doctors and securities analysts expect most people now taking Sustiva and Truvada separately to switch to the new pill.
It is somewhat less certain how many people taking other drug combinations will switch. Some of them will not because the virus in their bodies is already resistant to one of the drugs in the new pill or because they cannot tolerate side effects. Sustiva, also known as efavirenz, can cause unsettlingly vivid dreams and birth defects.
In addition, the new salmon-colored pill is about 1,500 milligrams, the size of a large vitamin pill, and some people may find it difficult to swallow.
Going to a single pill could be especially important in poor countries, where patients have less access to medical care and more people are illiterate or uneducated. The vast majority of the nearly 40 million people in the world infected by H.I.V., the virus that causes AIDS, are in developing nations. In the United States there are about 1.1 million.
Bristol-Myers and Gilead say they will make the new pill available at a sharply reduced price for developing nations, but details are still being worked out. They are negotiating with Merck & Company, which sells efavirenz in those countries under the name stocrin.
A once-daily treatment did not become feasible until a few years ago, with the development of individual drugs that needed to be taken only once a day.
Still, no one company controlled all the drugs needed for an effective combination. It is rare for rivals to collaborate, though it has been done. Merck and Schering-Plough, for instance, have put two of their drugs into a combination cholesterol treatment called Vytorin.
Executives at Bristol-Myers, discussing in 2003 how to increase sales of Sustiva, came up with the idea of approaching Gilead, which already had two once-a-day pills, Viread, also known as tenofovir, and Emtriva, or emtracitabine. Gilead, based in Foster City, Calif., is now the largest supplier of H.I.V. drugs.
Talks were given further urgency when the F.D.A. summoned the two companies and Merck to a meeting in Washington in April 2004. The government was trying to encourage development of simpler pills as part of the president's plan to provide antiviral treatments to poor countries. The next month, the three companies announced their plan.
But carrying it out was not easy. Simply combining the three chemicals produced a mixture that melted easily.
"We made the first formulation and went out for lunch, and when we came back from lunch we had glue on our hands," said Reza Oliyai, a Gilead scientist. The eventual solution was to keep Truvada and Sustiva in separate layers.
It also took about a year to find a formulation that would produce the same level of the three drugs in a patient's blood as the three drugs taken separately, which is the main requirement for approval of a combination drug. Gilead tested five different formulations in healthy volunteers.
The failure of patients to take their drugs faithfully is a major problem, experts say, because it allows H.I.V. to develop resistance to the drugs.
Still, it is unclear exactly how much better people with H.I.V. will stick to a once-daily regimen compared with one requiring two pills a day.
Bob Huff, who edits a newsletter on new treatments for the Gay Men's Health Crisis, a patient advocacy group in New York, said a drug's potency and side effects were more important to patients than convenience.
Still, he said, "For some people it's just what they need to make treatment doable." A single pill may also mean a single insurance co-payment, he said, instead of two or three now that can cost people $100 a month.
Michael Weinstein, president of the AIDS Healthcare Foundation, a Los Angeles organization that runs clinics in the United States and abroad, said other problems besides inconvenience — like drug addiction, depression and mental illness — kept people from sticking to their AIDS drugs.
Still, Mr. Weinstein called the new pill a "high-water mark" for simplicity and the way it was developed. "To have two companies collaborating — that's going to be significant for the future if it sets an example."
While other companies are expected to try to develop once-daily treatments, no other existing drugs can yet be as readily combined, said Dr. Calvin Cohen, research director for the Community Research Initiative of New England, a nonprofit organization that does clinical trials of H.I.V. drugs and provides patient education.
Dr. Cohen, an adviser to Gilead, Bristol-Myers and other drug manufacturers, said there was already some concern among AIDS experts that having a once-a-day treatment would make people lose their fear of H.I.V. "We still want people to respect that prevention of the disease is better than treatment," he said.
"We made the first formulation and went out for lunch, and when we came back from lunch we had glue on our hands," said Reza Oliyai, a Gilead scientist. The eventual solution was to keep Truvada and Sustiva in separate layers.
It also took about a year to find a formulation that would produce the same level of the three drugs in a patient's blood as the three drugs taken separately, which is the main requirement for approval of a combination drug. Gilead tested five different formulations in healthy volunteers.
The failure of patients to take their drugs faithfully is a major problem, experts say, because it allows H.I.V. to develop resistance to the drugs.
Still, it is unclear exactly how much better people with H.I.V. will stick to a once-daily regimen compared with one requiring two pills a day.
Bob Huff, who edits a newsletter on new treatments for the Gay Men's Health Crisis, a patient advocacy group in New York, said a drug's potency and side effects were more important to patients than convenience.
Still, he said, "For some people it's just what they need to make treatment doable." A single pill may also mean a single insurance co-payment, he said, instead of two or three now that can cost people $100 a month.
Michael Weinstein, president of the AIDS Healthcare Foundation, a Los Angeles organization that runs clinics in the United States and abroad, said other problems besides inconvenience — like drug addiction, depression and mental illness — kept people from sticking to their AIDS drugs.
Still, Mr. Weinstein called the new pill a "high-water mark" for simplicity and the way it was developed. "To have two companies collaborating — that's going to be significant for the future if it sets an example."
While other companies are expected to try to develop once-daily treatments, no other existing drugs can yet be as readily combined, said Dr. Calvin Cohen, research director for the Community Research Initiative of New England, a nonprofit organization that does clinical trials of H.I.V. drugs and provides patient education.
Dr. Cohen, an adviser to Gilead, Bristol-Myers and other drug manufacturers, said there was already some concern among AIDS experts that having a once-a-day treatment would make people lose their fear of H.I.V. "We still want people to respect that prevention of the disease is better than treatment," he said.
"We made the first formulation and went out for lunch, and when we came back from lunch we had glue on our hands," said Reza Oliyai, a Gilead scientist. The eventual solution was to keep Truvada and Sustiva in separate layers.
It also took about a year to find a formulation that would produce the same level of the three drugs in a patient's blood as the three drugs taken separately, which is the main requirement for approval of a combination drug. Gilead tested five different formulations in healthy volunteers.
The failure of patients to take their drugs faithfully is a major problem, experts say, because it allows H.I.V. to develop resistance to the drugs.
Still, it is unclear exactly how much better people with H.I.V. will stick to a once-daily regimen compared with one requiring two pills a day.
Bob Huff, who edits a newsletter on new treatments for the Gay Men's Health Crisis, a patient advocacy group in New York, said a drug's potency and side effects were more important to patients than convenience.
Still, he said, "For some people it's just what they need to make treatment doable." A single pill may also mean a single insurance co-payment, he said, instead of two or three now that can cost people $100 a month.
Michael Weinstein, president of the AIDS Healthcare Foundation, a Los Angeles organization that runs clinics in the United States and abroad, said other problems besides inconvenience — like drug addiction, depression and mental illness — kept people from sticking to their AIDS drugs.
Still, Mr. Weinstein called the new pill a "high-water mark" for simplicity and the way it was developed. "To have two companies collaborating — that's going to be significant for the future if it sets an example."
While other companies are expected to try to develop once-daily treatments, no other existing drugs can yet be as readily combined, said Dr. Calvin Cohen, research director for the Community Research Initiative of New England, a nonprofit organization that does clinical trials of H.I.V. drugs and provides patient education.
Dr. Cohen, an adviser to Gilead, Bristol-Myers and other drug manufacturers, said there was already some concern among AIDS experts that having a once-a-day treatment would make people lose their fear of H.I.V. "We still want people to respect that prevention of the disease is better than treatment," he said.
"Source":[ http://www.nytimes.com/2006/07/09/health/09aids.html?pagewanted=2&ei=5099&en=143155602ef3d493&ex=1153022400&partner=TOPIXNEWS]
Related articles
Montreal Researchers Make a Major Strategic Breakthrough in Controling the AIDS Virus - Dr (31.8.2006)
